October 23, 2007 - PLC Systems Inc. introduced at TCT 2007 the RenalGuard System, an investigational system and therapy that targets patients with compromised renal function who may be at risk for contrast-induced nephropathy, or CIN, when undergoing cardiovascular imaging procedures.
Sponsored by the Cardiovascular Research Foundation, this was the first public showing for this technology in the United States. RenalGuard Therapy is based on initial pre-clinical study data that suggests that initiating and maintaining high urine output during imaging procedures allows the body to rapidly eliminate toxins in contrast media, reducing their harmful effects. The RenalGuard System is a fully- automated, real-time matched fluid replacement device intended for the at-risk segment of the millions of interventional cardiology and radiology patients undergoing these procedures.
Earlier this year, the company announced it had enrolled the first patients in its FDA-approved pilot clinical trial designed to evaluate the safety of its RenalGuard System. Safety results were favorable, and there were no adverse renal events related to the device recorded.
For more information: www.plcmed.com